Potent Lipoglycopeptide Antibiotics Against C. Difficile

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1063214

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

In some people C. difficile bacteria naturally reside in the gut. Other people accidentally ingest spores of the bacteria while they are patients in a hospital or nursing home. Sometimes, broad-spectrum antibiotics used to treat an infection also kill healthy gut bacteria. The gut then becomes overrun with C. difficile, causing diarrhoea and pain, and sometimes death. We will investigate the use of a new potent antibiotic, vancapticin, to kill C. difficle and prevent relapse of infection.

Funded Activity Details

Start Date: 01-01-2014

End Date: 01-01-2016

Funding Scheme: Project Grants

Funding Amount: $750,411.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical Bacteriology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibiotic resistance | antibiotics | bacterial infection | diarrhoea | drug discovery | mechanism of action

Related Links